Does a cholesterol drug help prevent heart problems in high-risk people who haven’t had a heart attack or stroke?

Original Title

Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.

Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms

Summary

A drug called evolocumab was tested in people with diabetes or artery disease but no prior heart attack or stroke. It helped prevent heart attacks, strokes, and heart-related deaths.

Sign up to see full results

Get access to research results, context, and detailed analysis.

Surprising Findings

Evolocumab works powerfully even in people who’ve never had a heart attack or stroke.

Until now, PCSK9 inhibitors like evolocumab were mainly used after a cardiac event. This proves they can prevent first-time events — a major shift in prevention strategy.

Practical Takeaways

If you have diabetes or atherosclerosis and high cholesterol, ask your doctor if a PCSK9 inhibitor like evolocumab could reduce your first heart event risk.

high confidence

Unlock Full Study Analysis

Sign up free to access quality scores, evidence strength analysis, and detailed methodology breakdowns.

95%
High QualityOverall Score

Publication

Journal

The New England journal of medicine

Year

2025

Authors

E. Bohula, N. Marston, Ajay K. Bhatia, Gaetano M. De Ferrari, Lawrence A. Leiter, José C. Nicolau, Jeong-Gun Park, J. Kuder, Sabina A. Murphy, E. Walsh, H. Wang, Vladimir Blaha, Andrzej Budaj, J. Cornel, A. Goudev, R. Kiss, A. Lorenzatti, A. Parkhomenko, M. Cyrille, G. Paiva da Silva Lima, E. Ohman, R. Giugliano, M. Sabatine

26 citations
Analysis v1